BioVersys AG BIOV

BASEL, SWITZERLAND - September 3, 2026 (NEWMEDIAWIRE) - BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infection...

BASEL, SWITZERLAND - April 30, 2026 (NEWMEDIAWIRE) - BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections c...

Ad hoc announcement pursuant to Art. 53 LRBASEL, Switzerland, April 16, 2026 (GLOBE NEWSWIRE) -- BV100 is a potential best-in-class anti-infective agent in treating hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP) caused by carbapenem-resistant Acinetobacter baumannii (CRAB).The RIV-TARGET Phase 3 clinical trial (NCT07326540) aims to compare BV100 plus low-dose polymyxin B to Colistin plus high-dose ampicillin-sulbactam in patients with suspected H

BASEL, Switzerland, April 13, 2026 (GLOBE NEWSWIRE) -- BioVersys and partners publish in the prestigious journal of Nature Communications pre-clinical development data of AlpE (alpibectir and ethionamide), an innovative drug combination that overcomes drug-resistance to Mycobacterium tuberculosis (Mtb).Alpibectir is a potential first-in-class molecule for treating drug-resistant tuberculosis (TB) by targeting new bioactivation pathways exploited by ethionamide in Mtb.Pre-clinical data show that

Ad hoc announcement pursuant to Art. 53LR BASEL, Switzerland, Dec. 11, 2025 (GLOBE NEWSWIRE) -- BV100 Phase 3 in Ventilator Associated Bacterial Pneumonia initiated with first country submission completed and first patients to be dosed in the coming months – Phase 3 read-out expected in H2 2027Significant value inflection points achieved in 2025 including: Successful IPO on SIX Swiss Exchange extending cash runway to 2028, Strong BV 100 Phase 2 data generated in VABP, Global Research Collaborati